Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autovaccine versus suppressive antibiotic therapy for chronic hip or knee prosthesis infection
2022-004192-16Phase 3Active
- Sponsor
- IDIVAL
- Start
- Feb 2023
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of bacterial autovaccine, amoxicillin, trimethoprim + sulfamethoxazole, doxycycline, metronidazole and 5 more in periprosthetic joint infection (PJI) (2 arms), sponsored by IDIVAL. Primary endpoint: Clinical course. Started Feb 2023; status: active.
02
Drugs
bacterial autovaccineamoxicillintrimethoprim + sulfamethoxazoledoxycyclinemetronidazole
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on 2022-004192-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004192-16.